About incannex healthcare inc - IXHL
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.
IXHL At a Glance
Incannex Healthcare, Inc.
8 Century Circuit
Norwest, New South Wales (NSW) 2153
| Phone | 61-4-984-0786 | Revenue | 86.00K | |
| Industry | Biotechnology | Net Income | -46,885,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 616.667% | |
| Fiscal Year-end | 06 / 2026 | Employees | 12 | |
| View SEC Filings |
IXHL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 86.416 |
| Price to Book Ratio | 3.132 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.312 |
| Enterprise Value to Sales | -85.456 |
| Total Debt to Enterprise Value | -0.035 |
IXHL Efficiency
| Revenue/Employee | 7,166.667 |
| Income Per Employee | -3,907,083.333 |
| Receivables Turnover | 0.019 |
| Total Asset Turnover | 0.005 |
IXHL Liquidity
| Current Ratio | 2.858 |
| Quick Ratio | 2.858 |
| Cash Ratio | 2.153 |
IXHL Profitability
| Gross Margin | -186.047 |
| Operating Margin | -27,661.628 |
| Pretax Margin | -56,559.302 |
| Net Margin | -54,517.442 |
| Return on Assets | -250.093 |
| Return on Equity | -381.086 |
| Return on Total Capital | -343.555 |
| Return on Invested Capital | -376.738 |
IXHL Capital Structure
| Total Debt to Total Equity | 1.927 |
| Total Debt to Total Capital | 1.891 |
| Total Debt to Total Assets | 1.262 |
| Long-Term Debt to Equity | 0.553 |
| Long-Term Debt to Total Capital | 0.542 |